A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM (ATTRiumph)
13 luglio 2026 aggiornato da: AstraZeneca
A Phase IIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo in Adult Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Panoramica dello studio
Stato
Attivo, non reclutante
Intervento / Trattamento
Descrizione dettagliata
This is a Phase IIb, multicenter, double-blind study in 326 participants, who will be randomized to receive either eplontersen and ALXN2220 or eplontersen and placebo once every four weeks.
Participants will also receive daily supplemental doses of the recommended daily allowance of vitamin A.
Tipo di studio
Interventistico
Iscrizione (Stimato)
326
Fase
- Fase 2
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Research Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Research Site
-
Toronto, Ontario, Canada, M5G 2C4
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Research Site
-
-
-
-
-
Beijing, Cina, 100730
- Research Site
-
Beijing, Cina, 100034
- Research Site
-
Changsha, Cina, 410012
- Research Site
-
Chongqing, Cina, 400042
- Research Site
-
Guangzhou, Cina, 510080
- Research Site
-
Hangzhou, Cina, 310009
- Research Site
-
-
-
-
-
Créteil, Francia, 94010
- Research Site
-
Marseille, Francia, 13005
- Research Site
-
Rennes, Francia, 35033
- Research Site
-
Toulouse, Francia, 31059
- Research Site
-
-
-
-
-
Berlin, Germania, 10117
- Research Site
-
Cologne, Germania, 50937
- Research Site
-
Essen, Germania, 45147
- Research Site
-
Hamburg, Germania, 22767
- Research Site
-
Heidelberg, Germania, 69120
- Research Site
-
Homburg, Germania, 66421
- Research Site
-
München, Germania, 81377
- Research Site
-
Münster, Germania, 48149
- Research Site
-
-
-
-
-
Bunkyō City, Giappone, 113-8431
- Research Site
-
Kurume-shi, Giappone, 830-0011
- Research Site
-
Sapporo, Giappone, 060-8543
- Research Site
-
Shinjuku-ku, Giappone, 160-8582
- Research Site
-
Suita, Giappone, 565-8565
- Research Site
-
-
-
-
-
Bologna, Italia, 40138
- Research Site
-
Florence, Italia, 50134
- Research Site
-
Milan, Italia, 20138
- Research Site
-
Padova, Italia, 35128
- Research Site
-
Pavia, Italia, 27100
- Research Site
-
Pisa, Italia, 56124
- Research Site
-
Torino, Italia, 10154
- Research Site
-
Torrette - Ancona, Italia, 60126
- Research Site
-
Trieste, Italia, IT-34149
- Research Site
-
-
-
-
-
London, Regno Unito, NW3 2QG
- Research Site
-
London, Regno Unito, NW10 2PB
- Research Site
-
-
-
-
-
Barcelona, Spagna, 08035
- Research Site
-
Jaén, Spagna, 23007
- Research Site
-
L'Hospitalet de Llobregat, Spagna, 08907
- Research Site
-
Majadahonda, Spagna, 28222
- Research Site
-
Málaga, Spagna, 29010
- Research Site
-
Pamplona, Spagna, 31008
- Research Site
-
Salamanca, Spagna, 37007
- Research Site
-
Valencia, Spagna, 46010
- Research Site
-
-
-
-
California
-
La Jolla, California, Stati Uniti, 92037
- Research Site
-
San Francisco, California, Stati Uniti, 94115
- Research Site
-
Stanford, California, Stati Uniti, 94305
- Research Site
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Research Site
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Research Site
-
Miami, Florida, Stati Uniti, 33176
- Research Site
-
Weston, Florida, Stati Uniti, 33331
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Research Site
-
St Louis, Missouri, Stati Uniti, 63110
- Research Site
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Research Site
-
Durham, North Carolina, Stati Uniti, 27710
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Research Site
-
-
Pennsylvania
-
Danville, Pennsylvania, Stati Uniti, 17822
- Research Site
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Research Site
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- Research Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Research Site
-
Houston, Texas, Stati Uniti, 77030
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84132
- Research Site
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Research Site
-
-
-
-
-
Gothenburg, Svezia, 413 45
- Research Site
-
Lund, Svezia, 22242
- Research Site
-
Stockholm, Svezia, 171 64
- Research Site
-
Uppsala, Svezia, 751 85
- Research Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Capable of giving informed consent.
Inclusion Criteria:
- Participant must be ≥ 18 years to ≤ 85 years at the time of signing the informed consent.
Participants who have a diagnosis of ATTR-CM with either wild-type or variant TTR genotype based on 1 of the following:
- Endomyocardial biopsy with confirmatory TTR amyloid typing OR
- Grade 2 or 3 cardiac uptake on 99mTc scintigraphy in the absence of monoclonal gammopathy OR
- Grade 2 or 3 cardiac uptake on 99mTc scintigraphy AND confirmatory TTR amyloid typing in the presence of monoclonal gammopathy.
- NYHA Class I to III at Screening and life expectancy of ≥ 1 year as per the Investigator's judgement.
- End-diastolic IVST ≥ 12 mm on echocardiography.
- NT-proBNP ≥ 600pg/mL for participants without ongoing atrial fibrillation/flutter at Screening or NT-proBNP ≥ 1200pg/mL for participants with ongoing atrial fibrillation/flutter at Screening.
Able to complete symptom-limited maximal CPET at Screening based on the following test criteria:
- Able to exercise to near exhaustion during CPET as exhibited by RER ≥ 1.0 during symptom-limited CPET conducted during screening.
- If participant does not achieve RER ≥1.0, the CPET may be repeated once, at least 48 hours but less than 2 weeks (but before randomization) after the initial test.
- Treated according to locally recognised guidelines on standard-of-care treatment for patients with HF. Therapy should have been individually optimised and stable for ≥ 4 weeks (except diuretics) and include, unless contraindicated or not tolerated, treatment of high BP (targeting SBP < 130 mmHg as suggested in 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America HF guidelines), and ischaemic heart disease.
- Willingness to adhere to daily self-administered vitamin A supplementation (3000 IU).
Exclusion Criteria:
- Known leptomeningeal amyloidosis.
- Known light chain (AL) or secondary (amyloid A) amyloidosis, or any other form of systemic amyloidosis.
- Cardiomyopathy not primarily caused by ATTR-CM, for example, cardiomyopathy primarily due to hypertension, valvular heart disease, or ischaemic heart disease per Investigator's assessment.
- Acute coronary syndrome, unstable angina, stroke, transient ischaemic attack, coronary revascularisation, cardiac device implantation, cardiac valve repair, or major surgery within 12 weeks of Screening.
- Uncontrolled hypertension (average resting SBP > 160 mmHg or DBP > 100 mmHg at Screening).
- Average resting SBP < 90 mmHg or symptomatic orthostatic hypotension, despite appropriate treatment, at Screening per Investigator's assessment.
- Uncontrolled ventricular clinically significant cardiac arrhythmia, per Investigator's assessment.
- Left ventricular ejection fraction < 30% on echocardiography measured locally at Screening.
- Severe pulmonary impairment (SpO₂ < 92%) defined as resting SpO₂ below 92% on room air, measured by pulse oximetry, indicative of severe lung disease. Participants requiring supplemental oxygen to maintain SpO₂ ≥ 92%.
- Participants with renal failure requiring dialysis.
- History of solid organ transplantation or ventricular assist device or listing for heart transplantation at Screening. Note: prior history of planned corneal transplant is not an exclusion criterion.
- Suspected or known intolerance/allergy to proteins or any components of the study intervention.
Any of the following results conducted at screening:
i) Haemoglobin <8g/dL for women or <9g/dL for men. ii) Platelet count <125 X10*9/L or other disorder associated with clinically significant thrombocytopenia.
iii) ALT >2.0 X ULN iv) TBL >2.5 X ULN (participants with known Gilbert's syndrome can be included with TBL >2.5 X ULN as long as direct bilirubin is ≤ 1.5 X ULN) v) Serum retinol level < LLN vi) By CKD-EPI formula, eGFR <20 mL/min/1.73 m2 measured by the central laboratory at Screening.
- Current unstable liver or biliary disease per Investigator's assessment.
- Multiple myeloma, lymphoma, leukemia, or any malignancy or clonal stem cell disorder within the past 5 years (except basal cell or squamous epithelial carcinomas of the skin, melanoma in situ or cervical carcinoma in situ that have been curatively resected, Stage I cancer in remission, or adequately treated prostate cancer stage I, IIA, or IIB with Gleason score ≤ 3+4 and prostate-specific antigen < 20 ng/mL).
- Any prior treatment with an ATTR amyloid depleter or a TTR gene silencing agent approved or in clinical development.
- Participated in a structured exercise training programme within the 1 month prior to Screening or planned to start during the trial.
- Participation in another investigational clinical study or intake of another investigational drug within 30 calendar days or 5 half-lives of the IMP, whichever is longer before signing the ICF.
- Judgement by the Investigator that the participant should not participate in the study if the participant has a known medical or psychological condition or other risk factor that might interfere with the participant's full participation in the study, pose any additional risk for the participant, or confound the assessment of the participant or outcome of the study.
- Previous enrolment or randomisation in the present study.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Eplontersen and ALXN2220
Subcutaneous eplontersen and intravenous ALXN2220 every 4 weeks
|
Eplontersen delivered subcutaneously, once every 4 weeks
ALXN2220 delivered intravenously, once every 4 weeks
|
|
Comparatore placebo: Eplontersen and placebo
Subcutaneous eplontersen and intravenous placebo every 4 weeks
|
Eplontersen delivered subcutaneously, once every 4 weeks
Placebo delivered intravenously, once every 4 weeks
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cardiopulmonary exercise test peak VO2
Lasso di tempo: 52 week
|
Change from baseline in Cardiopulmonary exercise test peak VO2 at week 52
|
52 week
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
NT-proBNP
Lasso di tempo: 52 week
|
Change from baseline in NT-proBNP at week 52
|
52 week
|
|
Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score
Lasso di tempo: 52 week
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52. The minimum score is 0 and maximum score is 100. Higher scores indicate better health status. |
52 week
|
|
Extracellular volume
Lasso di tempo: 52 week
|
Change from baseline in Extracellular volume (subgroup) at week 52
|
52 week
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
11 giugno 2026
Completamento primario (Stimato)
6 febbraio 2029
Completamento dello studio (Stimato)
6 febbraio 2029
Date di iscrizione allo studio
Primo inviato
12 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
19 maggio 2026
Primo Inserito (Effettivo)
27 maggio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
14 luglio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
13 luglio 2026
Ultimo verificato
1 luglio 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D8456C00001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Sì
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .